Stanley-Laman Group’s NovoCure NVCR Stock Holding History

Stanley-Laman Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,013	Closed	-$466K	–	290
2021 Q3	$466K	Buy	+4,013	New	+$607K	0.06%	227

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stanley-Laman Group's NVCR Position: Q4 2021 in Review

Stanley-Laman Group sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 4,013 shares — an estimated $466K sold.

Stanley-Laman Group first reported a position in NVCR in Q3 2021 and held it in 1 quarter. The position peaked at $466K in Q3 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

Stanley-Laman Group reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
Stanley-Laman Group sold 4,013 NovoCure shares in Q4 2021, an estimated $466K.
Stanley-Laman Group first reported a position in NovoCure in Q3 2021 and held it in 1 quarter.
Stanley-Laman Group's NovoCure position peaked at $466K in Q3 2021.
311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Stanley-Laman Group's 13F filing for Q4 2021, filed 25 Jan 2022.